<DOC>
	<DOCNO>NCT02974244</DOCNO>
	<brief_summary>Exenatide weekly ( Bydureon ) approve January 2012 FDA USA treatment type 2 diabetes mellitus . Evidence clinical trial suggest Bydureon improves glucose control low risk hypoglycemia . Bydureon require dose titration necessary glucagon-like peptide-1 agonist , appear advantage , reduce insulin resistance , reduce weight , improve blood pressure lipid profile . However , degree advantage Bydureon lead improve outcome customary clinical care unknown . The aim study evaluate effectiveness tolerability Bydureon relative basal insulin initiate first-ever injectable therapeutic regimen use customary clinical care . Patients initiated treatment Bydureon basal insulin July 2011 March 2015 recruit study cohort Optum 's database electronic health record . The two treatment cohort match propensity score method.Clinical outcome HbA1c , weight , gastrointestinal symptom hypoglycemia investigate .</brief_summary>
	<brief_title>Comparison Effectiveness Tolerability Exenatide Once-weekly Compared Basal Insulins</brief_title>
	<detailed_description>Background : In January 2012 , US Food Drug Administration approve once-weekly form exenatide , Bydureon , treatment type 2 diabetes mellitus . Evidence clinical trial suggest Bydureon improves glucose control low risk hypoglycemia . Bydureon require dose titration necessary glucagon-like peptide-1 receptor agonist ( GLP-1RAs ) , appear advantage , reduce insulin resistance , prevent weight gain , improve blood pressure lipid profile . However , degree advantage Bydureon lead improve outcome customary clinical care unknown . Aims : The aim study evaluate effectiveness tolerability Bydureon relative basal insulin initiate first-ever injectable therapeutic regimen use customary clinical care . The specific study objective follow : - To quantify effectiveness Bydureon initiation relative initiation basal insulin , improve : - Glycated hemoglobin ( HbA1c ) - Weight ( body mass index ( BMI ) ) - HbA1c simultaneous reduction weight - Blood pressure lipid profile - To monitor tolerability Bydureon initiation relative initiation basal insulin , occurrence : - Hypoglycemia - Gastrointestinal symptom ( nausea , vomit , diarrhea , constipation ) - Change marker renal disease ( estimate glomerular filtration rate ( eGFR ) , serum creatinine , albumin/creatinine ratio ( ACR ) , stability liver function test ( AST , ALT ) standard blood count ( white blood cell , red blood cell , Hematocrit , Hemoglobin , Platelet ) - To examine measure effectiveness tolerability within potentially vulnerable subgroup Bydureon basal insulin initiator : - Type 2 diabetes patient renal impairment - Elderly Type 2 diabetes patient - Type 2 diabetes patient minority race - Type 2 diabetes patient within strata HBA1c Design : This retrospective cohort study conduct use Optum 's electronic health record data July 2011 March 2015 identify injectable-naive Type 2 diabetes patient initiate either Bydureon basal insulin accrual period , January 2012 January 2015 . Injectable-naive Type 2 diabetes patient identify . Propensity score method use match initiator Bydureon basal insulin initiator . Study Population : The study population select electronic health recrod data include patient Type 2 diabetes initiate Bydureon basal insulin . Eligible patient : - Received care least 6 month prior date study drug initiation ( cohort entry ) least one outpatient clinic visit 6 month prior cohort entry ( baseline period ) ; - At least one diagnosis type 2 diabetes ( ICD-9 250.X0 250.X2 ) prior include date qualify drug initiation , prior diagnosis ( inclusive index date ) type 1 diabetes mellitus ( 250.X1 250.X3 ) , diagnosis gestational diabetes within previous 6 month ( inclusive index date ) ; - No evidence prior injectable antidiabetic treatment , specifically dispense GLP-1RA insulin drug 6-month baseline period . Outcomes Analysis : To measure effectiveness Bydureon relative basal insulin change HbA1c body weight , well change HbA1c simultaneous reduction weight . Changes BMI , lipid profile , blood pressure examine . These variable part clinical laboratory data electronic health record . Each outcome evaluate completeness , multiply impute , report across standardized time interval . HbA1c , weight BMI summarize baseline quarterly ( 3-month interval ) first year follow drug initiation . Lipid measurement blood pressure summarize baseline bi-annually ( 6-month interval ) first year follow drug initiation . To assess drug tolerability , incidence hypoglycemia , gastrointestinal symptom ( nausea , vomit , diarrhea , constipation ) assess . These outcome ascertain use ICD-9 algorithm apply structured field extract mention hypoglycemia use natural language processing ( NLP ) algorithm develop Optum apply free text clinical note available data . In addition stability renal function evaluate change eGFR , albumin/creatinine ratio ( ACR ) ; change serum hepatic enzyme [ aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ] , hematologic measure [ red blood cell count ( RBC ) , white blood cell count ( WBC ) , platelet ( PLT ) , hemoglobin ( Hgb ) hematocrit ( Hct ) evaluate . Each laboratory value evaluate completeness , multiply impute , report across standardized time interval . eGFR ACR summarized baseline quarterly ( 3-month interval ) first year follow drug initiation . Hepatic enzyme hematologic measure summarize baseline semi-annually ( 6-month interval ) first year follow drug initiation .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>At least 18 year old ; receive care document Electronic Health Records ( include least one outpatient provider visit ) minimum 6months prior index date ; least one diagnosis type 2 diabetes The International Classification Diseases , Ninth Revision , Clinical Modification ( ICD9CM : 250.X0 250.X2 ) prior include date study drug initiation , prior diagnosis type1 diabetes ( ICD9CM : 250.X1 250.X3 ) , gestational diabetes within 6months prior index date ; No evidence prior injectable antidiabetic treatment , specifically dispense GLP1RA insulin 6months baseline period prior study drug initiation Prior diagnosis type1 diabetes ( ICD9CM : 250.X1 250.X3 ) , gestational diabetes within 6months prior index date ; Prior dispense GLP1RA insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 2 diabetes</keyword>
</DOC>